Report Overview

Global Peptide and Anticoagulant Drugs Market are flourishing owing to the increasing prevalence of ischemic heart disease and venous thromboembolism (VTE), rising usage of peptide and anticoagulant drugs, along with the increased awareness of novel oral anticoagulants (NOACs)...

Global Peptide and Anticoagulant Drugs Market - Industry Trends & Forecast Report 2028

Global Peptide and Anticoagulant Drugs Market is projected to reach USD 2.15 billion by the year 2028, exhibiting a CAGR of 5.4% during the forecast period (2022-2028). The rapid expansion of the market is predominantly due to the rising use of peptide and anticoagulant medications, rising rates of ischemic heart disease and venous thromboembolism (VTE), and increased knowledge of new oral anticoagulants (NOACs). Also, increased healthcare spending, an aging population, and the prevalence of chronic diseases are all contributing to the growth of the peptide and anticoagulant drugs market. Moreover, there are more peptide and anticoagulant medication cases, which gives other pharmaceutical companies a chance to deliver breakthrough therapies and exciting pipeline drugs. Additionally, recent drug approvals and improvements in treatment rates are two other reasons that are influencing the market for peptide and anticoagulant therapies. Furthermore, people's growing understanding of the benefits of early testing is also helping the market to grow.

Peptide and Anticoagulant Drugs - Overview

Anticoagulants are chemical substances that prevent blood from coagulating and from clotting quickly. Drugs of the pharmacological class of anticoagulants are used to treat thrombotic disorders. There are pill, tablet, and injectable dosage forms for oral anticoagulants. The most popular anticoagulants include warfarin, factor Xa inhibitors, low molecular weight heparins (LMWHs), herapins, and warfarin (DTIs). An injectable anticoagulant called heparin is frequently used in hospitals to stop blood clotting. Twice daily LMWH injections into the subcutaneous tissue are used to treat DVT. Long-chain amino acids are joined by peptide bonds, often referred to as amide bonds. The unique family of therapeutic compounds known as peptides is composed molecularly of both proteins and small molecules. To treat diseases, peptides' therapeutic properties are used.

Global Peptide and Anticoagulant Drugs Market Forecast and Trends

Growth Drivers

Growing Prevalence of Cardiovascular Disorders

Cardiovascular disorders are becoming more common, which further spurs industry expansion. The sector is growing as a result of the increase in cardiovascular diseases. The market is expanding mostly due to cardiovascular problems. According to the Heart Disease and Stroke Statistics Update Fact Sheet issued in 2021, cardiovascular disorders are the leading cause of death worldwide, accounting for nearly 18.6 million deaths in 2019. Cardiovascular diseases kill more people annually than both cancer and chronic lower respiratory disease (CLRD) put together. Also predicted to accelerate the market's growth pace is the rising prevalence of chronic disorders in both the elderly and middle-aged populations. Moreover, the market for peptide and anticoagulant medications is anticipated to grow because of the world's aging population and an increase in the number of infected individuals. Along with this, favorable reimbursement policies, rising smoking addiction, prolonged sitting, and sedentary lifestyles of people, all contribute to the market's increased growth rate.

Rising Infrastructure Spending for the Healthcare Industry

The rising costs of healthcare, which contribute to the development of its infrastructure, are a significant factor affecting the market for peptide and anticoagulant medications. Additionally, several government agencies are working to strengthen the healthcare system by providing more funds, which will have an additional impact on the market's dynamics. All these factors boost the growth of the Global Peptide and Anticoagulant Drugs Market during the forecast period (2022-2028).

Technological Progress Drives Market Growth

Technological advancements in the development of anticoagulant products are expected to benefit the industry. According to a study published in the Frontier in Biotechnology and Bioengineering in December 2019, advanced technologies such as microfluidics, fluorescent microscopy, electrochemical sensing, photoacoustic detection, and micro/nano electromechanical systems (MEMS/NEMS) were used to develop highly accurate, robust, and cost-effective anticoagulant products.  Furthermore, the market's expansion is being fueled by an increase in the number of R&D activities and emerging new markets. These factors will provide favorable opportunities for the growth of the peptide and anticoagulant drug markets.

Restraints

Side Effects of Anticoagulants

Over the projected timeframe, anticoagulant side effects may stifle market expansion. The immune system produces antibodies against the body's platelets as a result of heparin-induced thrombocytopenia, which raises the risk of bleeding. For instance, 3.8 percent of the 450,000 adverse drug events reported to the FDA each year involved heparin, which decreased market revenue. In addition to other problems, warfarin can lead to chondrodysplasia punctata, asplenia, and foetal abnormalities. These unintended repercussions will reduce the value of the industry. Important market players are working to create fresh products, but adverse effects could make them less popular.

Impact of COVID-19 on Global Peptide and Anticoagulant Drugs Market

COVID-19 infection has a significant impact on the peptide and anticoagulant drug markets due to the rapid pace of research. According to a study published in the American Journal of Cardiovascular Drugs in 2020, more than ten clinical trials are underway to assess the potential of anticoagulants in COVID-19 patients, and research on parenteral administration strategies for these drugs for use in critically ill COVID-19 patients is being conducted. Furthermore, according to a World Health Organization Update published in January 2021, patients with COVID-19, both confirmed and suspected, should have access to follow-up care with low-dose anticoagulants. As a result, anticoagulant demand increased significantly during COVID-19.

Global Peptide and Anticoagulant Drugs Market - By Route of Administration

Based on the route of administration, the Global Peptide and Anticoagulant Drugs Market are segmented into Parenteral, Oral, Mucosal, and Others. Anticoagulants are administered orally or by injection. The majority of injectable forms are administered in a hospital setting. The type of anticoagulant prescribed is determined by the condition being avoided. Pradaxa (dabigatran), Xarelto (rivaroxaban), Eliquis (apixaban), and Savaysa are the four new oral anticoagulant drugs approved by the FDA since 2010. All four, like warfarin, are "blood thinners" that lower the overall risk of stroke associated with atrial fibrillation, but they can also cause bleeding. Moreover, Heparin is not absorbed orally, owing to its size and polyanionic charge, and is thus administered parenterally, via continuous or intermittent infusion or subcutaneous (SC) injection. Additionally, clinical guidelines recommend starting warfarin therapy early with parenteral anticoagulation therapy.

 

Global Peptide and Anticoagulant Drugs Market - By Application

Based on application, the Global Peptide and Anticoagulant Drugs Market is segmented into Diabetes, Infectious Product, Cancer, Osteoporosis, Cardiology, and Gynecology. The cardiology segment now has the biggest market share and is likely to continue to do so during the forecast period (2022-2028). The increasing number of people suffering from the cardiac disease is one of the factors that can be attributed to the segment's growth. This influences the cardiology segment to dominate the market share in the upcoming years.

Global Peptide and Anticoagulant Drugs Market - By End-User

Based on end-user, the Global Peptide and Anticoagulant Drugs Market is segmented into Hospitals, Clinics, Homecare, and Others. Among these, the hospital segment is expected to grow at the fastest rate during the forecast period. Anticoagulants are given either in oral form or by injection. Most injectable forms are administered in the hospital. The type of anticoagulant prescribed depends upon the condition being prevented. Moreover, it is projected that the ongoing observation and detailed care plans provided in hospitals would boost patient choice. Therefore, the adoption of peptides and anticoagulants in hospitals is anticipated to be fueled by the rising hospital admissions and demand for improved treatments.

Global Peptide and Anticoagulant Drugs Market - By Region

Geographically, the Global Peptide and Anticoagulant Drugs Market is segmented into North America, Europe, The Asia Pacific, Latin America, and The Middle East and Africa. In terms of revenue, North America dominated the market. The region's growth is attributed to high demand for novel therapeutics, a strong presence of market players, early diagnosis, developed healthcare infrastructure, a large target population, and a large target population. However, due to increased health awareness and the rising prevalence of cardiovascular disease and VTE, Asia Pacific is expected to grow at the fastest CAGR during the forecast period (2022-2028).

Competitive Landscape

The leading market players in the Global Peptide and Anticoagulant Drugs Market are F.Hoffmann-La Roche Ltd, Mylan, Teva Pharmaceutical Industries Ltd, Sanofi, Pfizer, GSK, Novartis AG, Allergan, Eisai Co Ltd, Merck & Co Inc, and other prominent players.

The Global Peptide and Anticoagulant Drugs Market is highly fragmented with the presence of several manufacturing companies in the country. The market leaders retain their supremacy by spending on research and development, incorporating cutting-edge technology into their goods, and releasing upgraded items for customers. Various tactics, including strategic alliances, agreements, mergers, and partnerships, are used.

Recent Development

• In December 2020, Takeda Pharmaceutical Company Limited and PeptiDream Inc. entered into collaborative research and exclusive license agreement to create peptide-drug conjugates (PDCs) for neuromuscular diseases.
• In December 2020, Natco Pharma announced the launch of an anticoagulant medication named Rivaroxaban (RPIGAT). Rivaroxaban is an anticoagulant drug that treats and prevents blood clots. In India, Bayer markets the drug as Xarelto.

 Scope of the Report

Attributes	Details
Years Considered	Historical data – 2018-2021
	Base Year – 2021
	Forecast – 2022 – 2028
Facts Covered	Revenue in USD Billion
Product Service/Segmentation	By Route of Administration, By Product, By Application, By End-User, By Region
Key Players	F.Hoffmann-La Roche Ltd, Mylan, Teva Pharmaceutical Industries Ltd, Sanofi, Pfizer, GSK, Novartis AG, Allergan, Eisai Co Ltd, Merck & Co Inc, and other prominent players

 

 

By Route of Administration

• Parenteral
• Oral
• Mucosal
• Others

By Product

• Hormonal
• Antibiotic
• ACE Inhibitor
• Antifungal
• Others

By Application

• • Diabetes
  • Infectious Product
  • Cancer
  • Osteoporosis
  • Cardiology
  • Gynecology

By End-User

• • Hospitals
  • Clinics
  • Homecare
  • Others

By Region

• • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

 

1. Research Framework
   1. Research Objective
   2. Product Overview
   3. Market Segmentation
2. Research Methodology
   1. Qualitative Research
      1. Primary & Secondary Research
   2. Quantitative Research
   3. Market Breakdown & Data Triangulation
      1. Secondary Research
      2. Primary Research
   4. Breakdown of Primary Research Respondents
   5. Assumption & Limitation
3. Executive Summary
4. Global Peptide and Anticoagulant Drugs Market  Insights
   1. Industry Value Chain Analysis
   2. DROC Analysis
      1. Growth Drivers
      2. Restraints
      3. Opportunities
      4. Challenges
   3. Technological Advancement/Recent Development
   4. Regulatory Framework
   5. Porter’s Five Forces Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of New Entrants
      4. Threat of Substitutes
      5. Intensity of Rivalry
5. Global Peptide and Anticoagulant Drugs Market Overview
   1. Market Size & Forecast by Value, 2018-2028
      1. By Value (USD Million)
   2. Market Share & Forecast
      1. By Route of Administration
         1. Parenteral
         2. Oral
         3. Mucosal
         4. Others
      2. By Product
         1. Hormonal
         2. Antibiotic
         3. ACE Inhibitor
         4. Antifungal
         5. Others
      3. By Application
         1. Diabetes
         2. Infectious Product
         3. Cancer
         4. Osteoporosis
         5. Cardiology
         6. Gynecology
      4. By End-User
         1. Hospitals
         2. Clinics
         3. Homecare
         4. Others
      5. By Region
         1. North America
         2. Europe
         3. Asia Pacific
         4. Latin America
         5. Middle East and Africa
6. North America Peptide and Anticoagulant Drugs Market
   1. Market Size & Forecast by Value, 2018-2028
      1. By Value (USD Million)
   2. Market Share & Forecast
      1. By Route of Administration
      2. By Product
      3. By Application
      4. By End-User
      5. By Country
         1. United States
         2. Canada
7. Europe Peptide and Anticoagulant Drugs Market
   1. Market Size & Forecast by Value, 2018-2028
      1. By Value (USD Million)
   2. Market Share & Forecast
      1. By Route of Administration
      2. By Product
      3. By Application
      4. By End-User
      5. By Country
         1. Germany
         2. United Kingdom
         3. Italy
         4. France
         5. Spain
         6. Rest of Europe
8. The Asia Pacific Peptide and Anticoagulant Drugs Market
   1. Market Size & Forecast by Value, 2018-2028
      1. By Value (USD Million)
   2. Market Share & Forecast
      1. By Route of Administration
      2. By Product
      3. By Application
      4. By End-User
      5. By Country
         1. China
         2. India
         3. Japan
         4. South Korea
         5. Rest of Asia Pacific
9. Latin America Peptide and Anticoagulant Drugs Market
   1. Market Size & Forecast by Value, 2018-2028
      1. By Value (USD Million)
   2. Market Share & Forecast
      1. By Route of Administration
      2. By Product
      3. By Application
      4. By End-User
      5. By Country
         1. Brazil
         2. Mexico
         3. Rest of Latin America
10. The Middle East & Africa Peptide and Anticoagulant Drugs Market
    1. Market Size & Forecast by Value, 2018-2028
       1. By Value (USD Million)
    2. Market Share & Forecast
       1. By Route of Administration
       2. By Product
       3. By Application
       4. By End-User
       5. By Country
          1. Saudi Arabia
          2. UAE
          3. South Africa
          4. Rest of Middle East & Africa
11. Competitive Landscape
    1. List of Key Players and Their Offerings
    2. Market Share Analysis, 2021
    3. Competitive Benchmarking, By Operating Parameters
    4. Key Strategic Development (Merger, Acquisition, Partnership.)
12. Impact of Covid-19 on Global Peptide and Anticoagulant Drugs Market  
13. Company Profile (Company Overview, Financial Matrix, Competitive landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) **
    1. F.Hoffmann-La Roche Ltd
    2. Mylan
    3. Teva Pharmaceutical Industries Ltd
    4. Sanofi
    5. Pfizer
    6. GSK
    7. Novartis AG
    8. Allergan
    9. Eisai Co Ltd
    10. Merck & Co Inc
    11. Other Prominent Players

 

14. Key Strategic Recommendations

 

*Financial information in case of non-listed companies will be provided as per availability

**The segmentation and the companies are subjected to modifications based on in-depth secondary for the final deliverable

 

List of Figures

 

Figure 1: Global Peptide and Anticoagulant Drugs Market Segmentation

Figure 2: Global Peptide and Anticoagulant Drugs Market Industry Value Chain Analysis

Figure 3: Global Peptide and Anticoagulant Drugs Market Size, By Value (USD Million),2018-2028

Figure 4: Global Peptide and Anticoagulant Drugs Market Share (%), By Route of Administration, By Value, 2018-2028

Figure 5: Global Peptide and Anticoagulant Drugs Market Share (%), By Product, By Value, 2018-2028

Figure 6: Global Peptide and Anticoagulant Drugs Market Share (%), By Application, By Value, 2018-2028

Figure 7: Global Peptide and Anticoagulant Drugs Market Share (%), By End-User, By Value, 2018-2028

Figure 8: Global Peptide and Anticoagulant Drugs Market Share (%), By Country, By Value, 2018-2028

Figure 9: North America Peptide and Anticoagulant Drugs Market Size, By Value (USD Million), 2018-2028

Figure 10: North America Peptide and Anticoagulant Drugs Market Share (%), By Route of Administration, By Value, 2018-2028

Figure 11: North America Peptide and Anticoagulant Drugs Market Share (%), By Product, By Value, 2018-2028

Figure 12: North America Peptide and Anticoagulant Drugs Market Share (%), By Application, By Value, 2018-2028

Figure 13: North America Peptide and Anticoagulant Drugs Market Share (%), By End-User, By Value, 2018-2028

Figure 14: North America Peptide and Anticoagulant Drugs Market Share (%), By Country, By Value, 2018-2028    

Figure 15: Europe Peptide and Anticoagulant Drugs Market Size, By Value (USD Million), 2018-2028

Figure 16: Europe Peptide and Anticoagulant Drugs Market Share (%), By Route of Administration, By Value, 2018-2028

Figure 17: Europe Peptide and Anticoagulant Drugs Market Share (%), By Product, By Value, 2018-2028

Figure 18: Europe Peptide and Anticoagulant Drugs Market Share (%), By Application, By Value, 2018-2028

Figure 19: Europe Peptide and Anticoagulant Drugs Market Share (%), By End-User, By Value, 2018-2028

Figure 20: Europe Peptide and Anticoagulant Drugs Market Share (%), By Country, By Value, 2018-2028

Figure 21: Asia-Pacific Peptide and Anticoagulant Drugs Market Size, By Value (USD Million), 2018-2028

Figure 22: Asia-Pacific Peptide and Anticoagulant Drugs Market Share (%), By Route of Administration, By Value, 2018-2028

Figure 23:  Asia-Pacific Peptide and Anticoagulant Drugs Market Share (%), By Product, By Value, 2018-2028

Figure 24:  Asia-Pacific Peptide and Anticoagulant Drugs Market Share (%), By Application, By Value, 2018-2028 

Figure 25: Asia-Pacific Peptide and Anticoagulant Drugs Market Share (%), By End-User, By Value, 2018-2028 

Figure 26: Asia-Pacific Peptide and Anticoagulant Drugs Market Share (%), By Country, By Value, 2018-2028

Figure 27: Latin America Peptide and Anticoagulant Drugs Market Size, By Value (USD Million), 2018-2028

Figure 28: Latin America Peptide and Anticoagulant Drugs Market Share (%), By Route of Administration, By Value, 2018-2028

Figure 29: Latin America Peptide and Anticoagulant Drugs Market Share (%), By Product, By Value, 2018-2028

Figure 30: Latin America Peptide and Anticoagulant Drugs Market Share (%), By Application, By Value, 2018-2028

Figure 31: Latin America Peptide and Anticoagulant Drugs Market Share (%), By End-User, By Value, 2018-2028

Figure 32: Latin America Peptide and Anticoagulant Drugs Market Share (%), By Country, By Value, 2018-2028

Figure 33:  Middle East & Africa Peptide and Anticoagulant Drugs Market Size, By Value (USD Million), 2018-2028

Figure 34:  Middle East & Africa Peptide and Anticoagulant Drugs Market Share (%), By Route of Administration, By Value, 2018-2028

Figure 35: Middle East & Africa Peptide and Anticoagulant Drugs Market Share (%), By Product, By Value, 2018-2028

Figure 36:  Middle East & Africa Peptide and Anticoagulant Drugs Market Share (%), By Application, By Value, 2018-2028

Figure 37:  Middle East & Africa Peptide and Anticoagulant Drugs Market Share (%), By End-User, By Value, 2018-2028

Figure 38:  Middle East & Africa Peptide and Anticoagulant Drugs Market Share (%), By Country, By Value, 2018-2028

Figure 39: Global Peptide and Anticoagulant Drugs Market Share Analysis, 2021

 

List of Tables

 

Table 1: Global Peptide and Anticoagulant Drugs Market Size, By Route of Administration, By Value (USD Million), 2018-2028

Table 2: Global Peptide and Anticoagulant Drugs Market Size, By Product, By Value (USD Million), 2018-2028

Table 3: Global Peptide and Anticoagulant Drugs Market Size, By Application, By Value (USD Million), 2018-2028

Table 4: Global Peptide and Anticoagulant Drugs Market Size, By End-User, By Value (USD Million), 2018-2028

Table 5: Global Peptide and Anticoagulant Drugs Market Size. By Country, By Value (USD Million), 2018-2028

Table 6: North America Peptide and Anticoagulant Drugs Market Size, By Route of Administration, By Value (USD Million), 2018-2028

Table 7: North America Peptide and Anticoagulant Drugs Market Size, By Product, By Value (USD Million), 2018-2028

Table 8: North America Peptide and Anticoagulant Drugs Market Size, By Application, By Value (USD Million), 2018-2028

Table 9: North America Peptide and Anticoagulant Drugs Market Size, By End-User, By Value (USD Million), 2018-2028

Table 10: North America Peptide and Anticoagulant Drugs Market Size (USD Million), By Country, By Value 2018-2028 

Table 11: Europe Peptide and Anticoagulant Drugs Market Size, By Route of Administration, By Value (USD Million), By Value 2018-2028

Table 12: Europe Peptide and Anticoagulant Drugs Market Size, By Product, By Value (USD Million), By Value 2018-2028

Table 13: Europe Peptide and Anticoagulant Drugs Market Size, By Application, By Value (USD Million), By Value 2018-2028

Table 14: Europe Peptide and Anticoagulant Drugs Market Size, By End-User, By Value (USD Million), By Value 2018-2028

Table 15: Europe Peptide and Anticoagulant Drugs Market Size (USD Million), By Country, By Value 2018-2028

Table 16: Asia-Pacific Peptide and Anticoagulant Drugs Market Size, By Route of Administration, By Value (USD Million), By Value 2018-2028

Table 17:  Asia-Pacific Peptide and Anticoagulant Drugs Market Size (USD Million), By Route of Administration, By Value 2018-2028

Table 18:  Asia-Pacific Peptide and Anticoagulant Drugs Market Size (USD Million), By Product, By Value 2018-2028

Table 19: Asia-Pacific Peptide and Anticoagulant Drugs Market Size (USD Million), By Application, By Value 2018-2028

Table 20:  Asia-Pacific Peptide and Anticoagulant Drugs Market Size (USD Million), By End-User, By Value 2018-2028

Table 21: Asia-Pacific Peptide and Anticoagulant Drugs Market Size (USD Million), By Country, By Value 2018-2028

Table 22: Latin America Peptide and Anticoagulant Drugs Market Size, By Route of Administration, By Value (USD Million), By Value 2018-2028

Table 23: Latin America Peptide and Anticoagulant Drugs Market Size, By Product, By Value (USD Million), 2018-2028

Table 24: Latin America Peptide and Anticoagulant Drugs Market Size, By Application, By Value (USD Million), 2018-2028

Table 25: Latin America Peptide and Anticoagulant Drugs Market Size, By End-User, By Value (USD Million), 2018-2028

Table 26: Latin America Peptide and Anticoagulant Drugs Market Size (USD Million), By Country, By Value 2018-2028  

Table 27:  Middle East & Africa Peptide and Anticoagulant Drugs Market Size, By Route of Administration, By Value (USD Million), 2018-2028

Table 28:  Middle East & Africa Peptide and Anticoagulant Drugs Market Size, By Product, By Value (USD Million), 2018-2028

Table 29: Middle East & Africa Peptide and Anticoagulant Drugs Market Size, By Application, By Value (USD Million), 2018-2028

Table 30: Middle East & Africa Peptide and Anticoagulant Drugs Market Size, By End-User, By Value (USD Million), 2018-2028

Table 31:  Middle East & Africa Peptide and Anticoagulant Drugs Market Size (USD Million), By Country, By Value 2018-2028 

Table 32:  List of Key Players and Their Offerings

Table 33:  Competitive Benchmarking, by Operating Parameters

Table 34        F.Hoffmann-La Roche Ltd Company Overview

Table 35        F.Hoffmann-La Roche Ltd Financial Overview

Table 36        Mylan Company Overview

Table 37        Mylan Financial Overview

Table 38        Teva Pharmaceutical Industries Ltd Company Overview

Table 39        Teva Pharmaceutical Industries Ltd Financial Overview

Table 40        Sanofi Company Overview

Table 41        Sanofi Financial Overview

Table 42        Pfizer Company Overview

Table 43        Pfizer Financial Overview

Table 44        GSK Company Overview

Table 45        GSK Financial Overview

Table 46        Novartis AG Company Overview

Table 47        Novartis AG Financial Overview

Table 48        Allergan Company Overview

Table 49        Allergan AG Financial Overview

Table 50        Eisai Co Ltd Company Overview

Table 51        Eisai Co Ltd Financial Overview

Table 52        Merck & Co Inc Company Overview

Table 53        Merck & Co Inc Financial Overview